Cochrane · systematic review · CD010120
Non‐steroidal anti‐inflammatory drugs for acute gout
van Durme, CMPG, Wechalekar, MD, Landewé, RBM, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
20
No studies
1
Included studies
NR
No studies 1 · 4.8%Ungraded 0 · 0%Very low 0 · 0%Low 10 · 47.6%Moderate 10 · 47.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsNSAIDs compared to placebo for acute gout
Population: acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain: ≥ 50% improvement in pain (spontaneous pain at 24 hours) NSAIDs vs placebo | RR 2.75 [1.13, 6.72] | NR | Low Downgraded: risk of bias |
Inflammation: swelling NSAIDs vs placebo | RR 1.08 [0.79, 1.49] | NR | Low Downgraded: risk of bias |
Function: ≥ 50% improvement in pain with movement at 24 hours NSAIDs vs placebo | RR 4 [0.5, 31.74] | NR | Low Downgraded: risk of bias |
Participants' global assessment of treatment: not measured№. of participants: 30 (1 RCT) NSAIDs vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias |
Health‐related quality of life: not measured№. of participants: 30 (1 RCT) NSAIDs vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias |
Withdrawals due to adverse events NSAIDs vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Total adverse events NSAIDs vs placebo | RR 0.2 [0.01, 3.85] | NR | Low Downgraded: risk of bias |
Non‐selective NSAIDs versus selective cyclo‐oxygenase‐2 inhibitors
Population: acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain: mean change from baseline on 5‐point (0 to 4, 0 no pain) Likert scale Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Inflammation (swelling): mean change from baselineon 4‐point (0 to 3, 0 no swelling) Likert scale Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Function: mean change in pain with movement from baseline on4‐point (0 to 3, 0 best function) Likert scale Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors | no estimate extracted | NR | Low Downgraded: risk of bias |
Participants' global assessment of treatment successon 5‐point (0 very good) Likert scale Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Health‐related quality of life on SF‐36 (mental health component)Scale from 0 to 100 (0 worst quality of life) Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors | no estimate extracted | NR | Low Downgraded: risk of bias |
Withdrawals due to adverse events Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors | RR 2.34 [1.33, 4.14] | NR | Moderate Downgraded: risk of bias |
Total adverse events Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors | RR 1.94 [1.36, 2.78] | NR | Moderate Downgraded: risk of bias |
NSAIDs compared to glucocorticoids for acute gout
Population: acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain: mean decrease per hour on a VAS scale (0 to 100, 0 no pain) NSAIDs vs glucocorticoids | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Inflammation: swelling mean difference in change from baseline to 14 days NSAIDs vs glucocorticoids | no estimate extracted | NR | Low Downgraded: risk of bias |
Function: walking disability during first 6 hours NSAIDs vs glucocorticoids | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Patients' global assessment of treatment success at day 3 to 4 NSAIDs vs glucocorticoids | RR 0.92 [0.7, 1.22] | NR | Moderate Downgraded: risk of bias |
Health‐related quality of life (HRQoL)Not reported NSAIDs vs glucocorticoids | no estimate extracted | NR | No studies |
Withdrawals due to adverse events NSAIDs vs glucocorticoids | RR 2.8 [0.55, 14.22] | NR | Moderate Downgraded: risk of bias |
Total adverse events NSAIDs vs glucocorticoids | RR 1.62 [1.03, 2.55] | NR | Moderate Downgraded: risk of bias |